Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity raises target price on Personal Group

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on Personal Group from 316.0p to 368.0p on Wednesday following the firm's interim results. Canaccord Genuity noyed that Personal Group was "confident" in continuing progress in H2, with trading remaining in line with FY25 market expectations thus far.

The Canadian bank highlighted that Personal's affordable insurance offering had delivered "a particularly strong" six months, giving it confidence in its forecasts.

Canaccord Genuity also noted that Personal Group's balance sheet "remains very strong" and said it estimates roughly £17.0m available surplus cash, which could support strategic earnings-enhancing bolt-on acquisitions to provide additional products or expertise.

"We now value PGH at 18.7x CY25E P/E (previous: 16x), reflecting a re-rating of the relevant UK insurance peer group. We continue to note the CY24-26E EPS CAGR for PGH at 22.5% remains far superior to the peer group, which has an average forecast c.7% EPS CAGR over the same period," said Canaccord.

"The very strong earnings growth outlook, in addition to the B/S strength continues to justify a 50% P/E premium to the peer group for PGH in our view.""

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.